Patents Assigned to Merck
-
Publication number: 20250250486Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular energy efficient LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type. The media have an improved long-term stability against UV radiation and elevated temperatures.Type: ApplicationFiled: April 11, 2023Publication date: August 7, 2025Applicant: MERCK PATENT GmbHInventors: Harald HIRSCHMANN, Sabine SCHOEN, Philipp WUCHER
-
Patent number: 12377056Abstract: The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.Type: GrantFiled: February 5, 2020Date of Patent: August 5, 2025Assignee: MERCK SERONO SAInventors: H. James Brentzel, Jr., Maria Lopez-Bresnahan, Nazih Ammoury
-
Patent number: 12378273Abstract: The disclosed and claimed subject matter provides precursors having at least one tethered cyclopentadienyl ligand (“Cp ligand”), at least one amidinate ligand (“Ad ligand”) and a lanthanide and/or lanthanide-like transition metal (“M”) of the general formulae (i) (Cp ligand)2-M-(Ad ligand) or (ii) (Cp ligand)-M-(Ad ligand)2.Type: GrantFiled: November 18, 2021Date of Patent: August 5, 2025Assignees: Merck Patent GmbH, Versum Materials US, LLCInventors: Christoph Wetzel, Holger Heil, Michal Krompiec, Lars Lietzau, David Bruge, Ming Fang, Sergei V. Ivanov
-
Publication number: 20250243491Abstract: Disclosed herein are short interfering RNA (siRNA) molecules that downregulate expression of PNPLA3 or variants thereof. The siRNA molecules comprise modified nucleotides and uses thereof. The siRNA molecules may be double stranded and comprise modified nucleotides, such as 2?-O-methyl nucleotides and 2?-fluoro nucleotides, and ligands.Type: ApplicationFiled: September 1, 2022Publication date: July 31, 2025Applicants: Aligos Therapeutics, Inc., Merck Sharp & Dohme LLCInventors: Leonid BEIGELMAN, Xuan LUONG, Saul MARTINEZ MONTERO, Aneerban BHATTACHARYA, Jerome DEVAL
-
Patent number: 12365838Abstract: A method for preparing a switching element which is operable in and electrically switchable between an optically clear state and a scattering state, wherein one or more polymerisable mesogenic compounds provided in a layer containing a liquid-crystalline medium which comprises one or more mesogenic compounds, one or more chiral compounds and the one or more polymerisable mesogenic compounds are subjected to polymerisation in the presence of a direct current (DC) electric field in the layer. Also, a switching element obtained or respectively obtainable by carrying out the method and to the use of the switching element in a window.Type: GrantFiled: May 12, 2020Date of Patent: July 22, 2025Assignee: Merck Patent GmbHInventors: Roel van Raak, Paul Verbunt
-
Patent number: 12366562Abstract: A method is provided for preparing a sample of a specimen to be analysed from a thin-layer plate in thin-layer chromatography. The sample is removed from a surface of the thin-layer plate by means of a blade disposed at a receiving opening of a cannula and fed through the cannula to a specimen chamber connected to the cannula. A reduced pressure can be generated in the specimen chamber to suck the sample removed from the thin-layer plate by means of the cannula through the receiving opening into and through the cannula and into the specimen chamber. After removal and feed of the sample, the specimen chamber can be filled with a solvent to dissolve the sample.Type: GrantFiled: August 21, 2018Date of Patent: July 22, 2025Assignee: Merck Patent GmbHInventors: Sarah Heub, Aurele Horisberger, Younouss Faye, Jean-Baptiste Orhan, Olivier Marti
-
Publication number: 20250230185Abstract: Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from the production protein using chromatographic processes.Type: ApplicationFiled: January 16, 2025Publication date: July 17, 2025Applicant: Merck Sharp & Dohme LLCInventors: Rebecca A. Chmielowski, Francis K. Insaidoo, Justin B. Miller, David J. Roush, Darshini Shah, John P. Welsh
-
Publication number: 20250230359Abstract: The new media exhibit a ferroelectric nematic phase preferably at ambient temperature. They preferably comprise one or more compounds selected from the group of compounds of formulae IA, IB and IC, in which the variable groups have the meanings indicated in the text and in the claims. Use of the media for providing ferroelectric nematic materials and a method of operation of an electro-optical device are presented. The media may be useful for energy-saving displays and electrical appliances.Type: ApplicationFiled: December 27, 2024Publication date: July 17, 2025Applicant: MERCK PATENT GMBHInventors: Matthias BREMER, Atsutaka MANABE, Martin KRASKA
-
Publication number: 20250230882Abstract: The present application relates to a holder for a fluid connector fitting and to a fluid dispenser including the same.Type: ApplicationFiled: October 10, 2022Publication date: July 17, 2025Applicant: Merck Patent GmbHInventor: Stephane OLIVIER
-
Publication number: 20250230360Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular energy efficient LC displays of the TN, PSTN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type. The media have an improved long-term stability against UV radiation and elevated temperatures.Type: ApplicationFiled: April 11, 2023Publication date: July 17, 2025Applicant: MERCK PATENT GMBHInventors: Harald HIRSCHMANN, Sabine SCHOEN, Philipp WUCHER
-
Patent number: 12359128Abstract: Heteroaromatic isothiocyanates of formula N wherein RN, AN1, AN2, ZN1, ZN2, W, X1, X2, and n are as defined herein can be used in liquid crystalline media. Liquid-crystalline media comprising one or more compounds of formula N are suitable for use in high-frequency components, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g., phased array antennas.Type: GrantFiled: December 14, 2021Date of Patent: July 15, 2025Assignee: MERCK PATENT GMBHInventors: Constanze Brocke, Dagmar Klass, Carsten Fritsch, Amir Hossain Parham
-
Patent number: 12359164Abstract: The present invention relates to a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to cell culture media with improved solubility without changing the chemical composition.Type: GrantFiled: March 19, 2021Date of Patent: July 15, 2025Assignee: Merck Patent GmbHInventors: Joerg Von Hagen, Nikolai Stankiewicz, Anke Simon
-
Patent number: 12360453Abstract: A resist composition which has as components a phenolic resin component, a photoactive 2,1,5-diazonaphthoquinonesulfonate component (PAC), a solvent component and that does not contain a photo acid generator (PAG). The PAC is a free PAC, a coupled PAC (PACb) or a combination thereof that includes a substituted or unsubstituted 2,1,5-DNQ material or compound onto which a substituted or unsubstituted 2,1,5-DNQ material is appended that, when UV exposed, do not form sulfonic acid. The phenolic resin component is a Novolak derivative in which some or all the free hydroxy groups are protected with an acid cleavable acetal moiety which can include a PACb moiety. A method whereby this composition is used in either thick or thin film photoresist device manufacturing methodologies.Type: GrantFiled: November 17, 2020Date of Patent: July 15, 2025Assignee: Merck Patent GmbHInventors: Takanori Kudo, Hung-Yang Chen
-
Publication number: 20250223259Abstract: The present invention provides a compound of Formula I wherein A, M, R1, R2, R3a, R3b, and subscripts m and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 5, 2023Publication date: July 10, 2025Applicant: Merck Sharp & Dohme LLCInventors: Brian T. Campbell, Wonsuk Chang, Timothy J. Hartingh, Danielle M. Hurzy, Michael J. Kelly, III, Franca-Maria Klingler, Mark E. Layton, John A. McCauley, Christopher Charles Nawrat, Craig A. Parish, James J. Perkins, Anthony J. Roecker, Manuel de Lera Ruiz, John D. Schreier, Valerie W. Shurtleff, Jing Su, Quang T. Truong
-
Publication number: 20250223496Abstract: A liquid-crystal (LC) medium or LC material based on a mixture of polar compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the vertically aligned mode and/or the fringe-field switching mode, an LC display of the vertically aligned mode and/or the fringe-field switching mode comprising the LC medium, especially an energy-saving LC display, and a process of manufacturing the LC display.Type: ApplicationFiled: January 3, 2025Publication date: July 10, 2025Applicant: MERCK PATENT GmbHInventors: Harald HIRSCHMANN, Sabine SCHOEN
-
Publication number: 20250223290Abstract: Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.Type: ApplicationFiled: December 12, 2024Publication date: July 10, 2025Applicant: Merck Sharp & Dohme LLCInventors: Zachary G. Brill, Donna A.A.W. Hayes, Tom M. Lam, Kyle S. McClymont, Bryan S. Matsuura, Rohan Rajiv Merchant, Anilkumar G. Nair, Ning Qi
-
Patent number: 12351570Abstract: The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.Type: GrantFiled: December 20, 2019Date of Patent: July 8, 2025Assignee: MERCK PATENT GMBHInventors: Timo Heinrich, Carl Petersson, Mireille Krier, Andrzej Gondela, Michal Mikolaj Galezowski, Charles-Henry Robert Yves Fabritius, Mateusz Oktawian Nowak, Marcin Krol
-
Patent number: 12350270Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: GrantFiled: July 21, 2020Date of Patent: July 8, 2025Assignees: MSD R&D (China) Co. Ltd., The Walter and Eliza Hall Institute of Medical Research, Merck Sharp & Dohme LLCInventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
-
Patent number: 12351630Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: October 8, 2021Date of Patent: July 8, 2025Assignee: Merck Sharp & Dohme LLCInventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 12351594Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.Type: GrantFiled: April 8, 2020Date of Patent: July 8, 2025Assignee: Merck Patent GmbHInventors: Ilona Stengel, Aaron Lackner, Lara-Isabel Rodriguez, Charlotte Walter, Amel Mekic